drugset
drugset / Trial / NCT06680531

A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets

NCT06680531 ↗

Phase 1 Completed 24 enrolled Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
RandomizedParallel-groupSingle-blindBasic science

Summary

Primary Objective： 1\) To evaluate the pharmacodynamic interaction between YZJ-1139 tablets and Escitalopram oxalate tablets in healthy subjects; 2) To evaluate the pharmacokinetic interaction between YZJ-1139 tablets and Escitalopram oxalate tablets in healthy subjects; To observe the safety of YZJ-1139 tablets taken together with Escitalopram oxalate tablets.

Timeline

Start
2024-08-31
Primary completion
2024-09-19
Completion
2024-11-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule — Oral
Subject FAZAMOREXANT Small molecule — Oral

Indications

insomnia